Project Grant R35GM163463
- The National Institute of General Medical Sciences awarded The Regents of the University of California at Riverside $420,492 on July 10, 2026, as a Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to develop chemical synthesis strategies targeting underexplored protein receptors associated with cancer, Alzheimer's disease, and inflammatory disorders. The five-year research program (performance through April 30, 2031) focuses on three therapeutic axes:...
- The National Institute of General Medical Sciences awarded the University of California, Los Angeles $420,981 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop engineered enzymatic catalysts for asymmetric hydrogen atom transfer reactions in synthetic chemistry. The research integrates organic chemistry, protein engineering, bioinorganic chemistry, and computational modeling to design and evolve biocatalysts that enable...
- The National Institute of General Medical Sciences awarded the University of California, Irvine $126,489 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop computational methods integrating physics-based and machine learning approaches for accelerated drug discovery. The project addresses the high cost and extended timelines of small-molecule drug development by combining molecular dynamics-based binding free energy calculations with active...
- The National Institute of General Medical Sciences awarded California Institute of Technology $225,564 on January 20, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop an enantioselective dearomative cyclization strategy for synthesizing quinolizidine natural products. The research focuses on converting pyridine into enantioenriched quinolizidines in a single synthetic step using palladium catalysis and dynamic kinetic resolution. High-throughput data...
- The University of California Irvine received a $500,000 project grant award from the National Science Foundation to support strategy-guided syntheses of complex natural products from July 1, 2021 to June 30, 2024. The award is funded through the NSF's Mathematical and Physical Sciences program (CFDA 47.049), which aims to strengthen the nation's scientific enterprise through increased understanding of major problems. Under the award, UC Irvine will apply strategic methods to synthesize complex...
- The National Institute of General Medical Sciences awarded California Institute of Technology $446,219 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to advance selective reactions of carbocations in synthetic chemistry. The funded research expands enantioselective C-H insertion reactions of catalytically generated vinyl carbocations to access diverse cyclic and polycyclic systems. The work develops innovative electrophilic reactions and...
- The National Institute of General Medical Sciences awarded the University of California, Davis $675,667 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop chemoenzymatic strategies for synthesizing glycans and glycoconjugates. The research program focuses on two major directions: developing innovative chemoenzymatic methods for synthesizing complex bacterial surface glycans, including those with multiple polysaccharide repeating units applicable...
- The National Institute of General Medical Sciences awarded the University of California Irvine $487,953 on March 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate nitrogenase assembly and reactivity over five years. The research combines genetic, biochemical, spectroscopic, and structural approaches to understand how the M-cluster metallocofactor of molybdenum nitrogenase is assembled into a functional unit. Specific investigations include the...
- The National Institute of General Medical Sciences awarded the University of California Irvine $448,510 on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop bifunctional small-molecule degraders that target the proteasome-mediated protein degradation pathway for cancer and protein accumulation diseases. The project will develop RPN-13-binding degraders, a new class of molecules that direct proteins of interest to the proteasome entrance without...
- The National Institute of General Medical Sciences, a bureau of the National Institutes of Health within the Department of Health and Human Services, awarded $301,936 to the University of California, Los Angeles on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). The award funds data-science-guided study and design of phosphoranyl radical-mediated reactions for the discovery of novel pharmaceutical compounds. The research builds a comprehensive,...
The National Institute of General Medical Sciences awarded the University of California Irvine $526,832 on August 10, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to advance stereoselective synthesis methods inspired by natural products. The award is a Project Grant designated R35GM163463 with performance through May 31, 2031, at the Irvine, California campus. The funded research develops novel organic synthesis reactions designed to enable discovery of natural product-inspired medicinal agents. The investigator's prior work includes over thirty-five stereoselective reactions based on metallacycle-mediated cross-coupling, sigmatropic rearrangement, cycloaddition, vinylcyclopropane rearrangement, radical cascades, and tandem oxidative dearomatization. These synthesis advances have supported downstream discovery of specific therapeutic agents including a non-opioid analgesic, HSP90 inhibitors, anti-multiple myeloma agents, p53 ligands, estrogen receptor agonists, glucocorticoid receptor modulators, androgen receptor antagonists, and GPR40 functional ligands. The program integrates reaction development, natural product synthesis, and application of in-house technology to drive molecular discovery across medicinal chemistry domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $526.8k | 8/5/26 |